Eligible commercially insured patients who are prescribed HEMLIBRA for an FDA-approved use can receive up to $15,000 per calendar year for drug costs. For more information, see full program Terms and Conditions.
Effective May 11, 2023, the HEMLIBRA Co-pay Program has two program updates:
- For pharmacy adjudicated claims, HEMLIBRA co-pay patients will utilize their new member ID along with the following new processing information that can be found in the patient record:
HEMLIBRA BIN: 610020, PCN: PDMI, Group Number: 99995209
- Eligible commercially insured patients in the HEMLIBRA Co-pay Program may now pay as little as $0 co-pay for drug costs up to $15,000 in assistance per calendar year.
Eligible claims submitted to the HEMLIBRA Co-pay Program with a date of service on or after May 11, 2023 will be processed and patients may pay as little as $0 co-pay.
For more information, please call the Help Desk at (844) 436-2672.
Call 
to change word size.